Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan
Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan.
In Vivo. 2019 Nov-Dec;33(6):2117-2123. doi: 10.21873/invivo.11712.
BACKGROUND/AIM: If VEGF inhibitors contribute to an increase in D-dimer levels, they may adversely affect the diagnosis of venous thromboembolism (VTE). Consequently, this retrospective study examined the effects of VEGF inhibitors on D-dimer levels in colorectal cancer patients.
A total of 104 colorectal cancer patients who received chemotherapy, were included in this study. To perform D-dimer analysis, patients were divided into two analysis targets: patients with VTE and without VTE. Statistical analysis included a natural logarithmic transformation of D-dimer data.
In the D-dimer analysis of non-VTE patients, the natural logarithm D-dimer mean difference was -0.186, with a 95% CI of -0.525 to 0.154. The upper limit of the 95%CI (0.154) did not exceed the non-inferiority margin (Δ) of 0.199, and therefore met the non-inferiority criteria.
VEGF inhibitors don't contribute to increased D-dimer levels in colorectal cancer patients without VTE.
背景/目的：如果血管内皮生长因子抑制剂导致 D-二聚体水平升高，它们可能会对静脉血栓栓塞症（VTE）的诊断产生不利影响。因此，本回顾性研究探讨了血管内皮生长因子抑制剂对结直肠癌患者 D-二聚体水平的影响。
本研究共纳入 104 例接受化疗的结直肠癌患者。为了进行 D-二聚体分析，患者被分为 VTE 患者和非 VTE 患者两组。统计分析包括对 D-二聚体数据进行自然对数转换。
在非 VTE 患者的 D-二聚体分析中，自然对数 D-二聚体平均差值为-0.186，95%CI 为-0.525 至 0.154。95%CI 的上限（0.154）未超过 0.199 的非劣效性边界（Δ），因此符合非劣效性标准。
在无 VTE 的结直肠癌患者中，血管内皮生长因子抑制剂不会导致 D-二聚体水平升高。
